Drug WatchNew Indication for IbrutinibAschenbrenner, Diane S. MS, RN Author Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: [email protected]. AJN, American Journal of Nursing: December 2017 - Volume 117 - Issue 12 - p 22 doi: 10.1097/01.NAJ.0000527482.48374.27 Buy Metrics Abstract Ibrutinib (Imbruvica), a drug previously approved to treat certain types of cancer, is now approved to treat chronic graft-versus-host disease when treatment with corticosteroids has failed. The majority of patients participating in a clinical trial of ibrutinib experienced improvement in their symptoms. For about half of these patients, improvement lasted five months or longer. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
